



Long-Term Effectiveness of iTrack™ MIGS Procedure to be Spotlighted at 2021 Swiss Society of Ophthalmology

Fremont, California, 25 August 2021 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to report the long-term results of a retrospective study assessing the clinical outcomes of iTrack™ ab-interno canaloplasty, to be presented at the 114th Annual Meeting of the Swiss Society of Ophthalmology, August 25-27, 2021.

Kevin Gillmann MD, MBBS, FEBOphth, will present the 36-month results, which analyzed the effectiveness and safety outcomes of 30 eyes (25 patients) diagnosed with uncontrolled primary open angle glaucoma (POAG) that underwent treatment with iTrack™ ab-interno canaloplasty in conjunction with cataract surgery.¹ Patients were classified as mild, moderate or severe POAG.

Dr. Gillmann is an ophthalmologist and glaucoma fellow at Moorfields Eye Hospital, London, United Kingdom. He previously served as a research coordinator at the Swiss Glaucoma Research Foundation.

The study had a mean follow-up period of 42.3 ± 4.6 months. Considering all eyes, intraocular pressure (IOP) decreased by 46.7% from 25.9 ± 9.2 mmHg at baseline to 13.8 ± 4.0 mmHg ($p < 0.001$) at the last follow-up visit. A significant reduction in the mean number of medications was also recorded, falling by 70.6% from 3.4 ± 0.9 at baseline to 1.0 ± 1.2 ($p < 0.001$).

In cases of moderate glaucoma (baseline MD < -9 dBs), 100% of patients achieved a reduction in mean IOP $\geq 20\%$ from baseline, with the number of medications reduced or unchanged as compared to baseline. iTrack™ ab-interno canaloplasty also demonstrated effectiveness in cases of later stage disease, including patients that had previously undergone filtering surgery.

The most common complication noted was IOP spikes (IOP > 30 mmHg) during the first post-operative week (36.7%). The majority of IOP spikes were transient and resolved with the short-term addition of aqueous suppressants, but some cases had persistent IOP elevation and required filtering surgery.



Dr. Gillmann and colleagues concluded that iTrack™ ab-interno canaloplasty achieved a statistically significant reduction in IOP and anti-glaucoma medications through three years of follow-up, with a favourable safety profile – and offers utility in the long-term control of IOP in cases of mild-to-severe open-angle glaucoma.

1. [6545] 36-Month outcomes of Combined Ab interno Visco canaloplasty (ABiC) in the Surgical Treatment of Open-Angle Glaucoma. K Gillmann¹, A. Aref², LJ Niegowski², J Baumgartner². 1 Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom, 2 Clinique de l’Oeil, Onex.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe or complex glaucoma. It also offers the benefit of a simplified and faster surgical profile. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com
